Literature DB >> 9630828

Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction.

H P Platten1, E Schweizer, K Dilger, G Mikus, U Klotz.   

Abstract

OBJECTIVE: To determine whether age-dependent pharmacokinetic and pharmacodynamic alterations account for a more pronounced response to benzodiazepines among elderly patients.
METHODS: Twelve young patients and 10 elderly patients received an intravenous dose of 0.05 or 0.03 mg/kg midazolan, respectively, before third molar extraction. Postoperative pain was treated with 30 mg dihydrocodeine. Serum concentrations of midazolam and sedative effects were monitored with visual analog scales and choice reaction time measurements for 6 hours. Test values above baseline were integrated, and pharmacokinetic-pharmacodynamic analysis was performed. Heart rate, blood pressure, arterial oxygen saturation, and amnesia also were assessed.
RESULTS: There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min). However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group. Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients. Amnesia was observed among 86% of patients and oxygen saturation was always 95% or more of basal value. There were no age-related differences in concentration of dihydrocodeine and its active metabolite dihydromorphine, but dihydromorphone levels were much lower in there intermediate metabolizers (455 to 879 fmol/l) and especially in five poor metabolizers (65 to 498 fmol/L) than among extensive metabolizer of cytochrome p450 2D6 (1604 to 6490 fmol/L).
CONCLUSION: Elderly patients are more sensitive to the sedative action of midazolam than young patients, and the sensitivity is caused by age-dependent pharmacodynamic alterations. The age-adjusted doses used are both effective (for sedative amnesia) and safe (in terms of arterial oxygen saturation, heart rate, and blood pressure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630828     DOI: 10.1016/S0009-9236(98)90106-0

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration.

Authors:  Hong-yun Wang; Xia Chen; Ji Jiang; Jun Shi; Pei Hu
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

Review 2.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 3.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

4.  Exposure to anticholinergic and sedative medicines as indicators of high-risk prescriptions in the elderly.

Authors:  Elodie Jean-Bart; Claire Moutet; Virginie Dauphinot; Pierre Krolak-Salmon; Christelle Mouchoux
Journal:  Int J Clin Pharm       Date:  2017-10-31

5.  Comparison of local spectral modulation, and temporal correlation, of simultaneously recorded EEG/fMRI signals during ketamine and midazolam sedation.

Authors:  Anna Forsyth; Rebecca McMillan; Doug Campbell; Gemma Malpas; Elizabeth Maxwell; Jamie Sleigh; Juergen Dukart; Joerg F Hipp; Suresh D Muthukumaraswamy
Journal:  Psychopharmacology (Berl)       Date:  2018-11-14       Impact factor: 4.530

6.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.

Authors:  Helmut Schmidt; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

9.  Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.

Authors:  M Pecking; F Montestruc; P Marquet; E Wodey; M-C Homery; P Dostert
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

10.  Interaction between midazolam and clarithromycin in the elderly.

Authors:  Sara K Quinney; Barbara D Haehner; Melissa B Rhoades; Zhen Lin; J Christopher Gorski; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.